{"created":"2023-07-27T06:29:43.778083+00:00","id":14495,"links":{},"metadata":{"_buckets":{"deposit":"27b16c02-6537-473c-8f02-b68f8c37cd80"},"_deposit":{"created_by":3,"id":"14495","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"14495"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00014495","sets":["1132:1133:1134"]},"author_link":["71","24460","25437","25439","20436","25438","25441","25440","235"],"item_4_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2011-06-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"6","bibliographicPageEnd":"545","bibliographicPageStart":"541","bibliographicVolumeNumber":"86","bibliographic_titles":[{"bibliographic_title":"European Journal of Haematology"}]}]},"item_4_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"A 1-yr-old Japanese male infant developed hepatitis-associated aplastic anemia (AA), and anti-thymocyte globulin (ATG) plus cyclosporine A (CsA) was administered without any appreciable effects. Laboratory examination of the patient's serum obtained before therapy revealed various autoantibodies, such as PA-IgG, anti-platelets, anti-single-stranded DNA (ssDNA), and anti-double-stranded DNA (dsDNA) antibodies (Abs) in addition to anti-DRS-1 Abs and anti-moesin Abs, both of which are known to be detectable in approximately 40% of all patients presenting with AA. He was therefore treated with 17.5mg/kg/d rituximab 5.5months after ATG/CsA therapy. The same rituximab therapy was repeated three times once a month thereafter. His neutrophil counts started to increase 50d after the first rituximab therapy and he achieved a complete remission at 16months after the last rituximab administration. All of the autoantibodies including anti-ssDNA, dsDNA, DRS-1, and moesin became undetectable when he attained the remission. Anti-CD20 monoclonal antibody therapy may be effective in a subset of patients with AA characterized by the presence of autoantibodies. © 2011 John Wiley & Sons A/S.","subitem_description_type":"Abstract"}]},"item_4_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学医薬保健研究域医学系","subitem_description_type":"Other"}]},"item_4_publisher_17":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Wiley-Blackwell"}]},"item_4_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1111/j.1600-0609.2011.01612.x","subitem_relation_type_select":"DOI"}}]},"item_4_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AA10668976","subitem_source_identifier_type":"NCID"}]},"item_4_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0902-4441","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Takamatsu, Hiroyuki"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Yagasaki, Hiroshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Takahashi, Yoshiyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hama, Asahito"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Saikawa, Yutaka"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Yachie, Akihiro"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"Koizumi, Shoichi"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Kojima, Seiji"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakao, Shinji"}],"nameIdentifiers":[{},{},{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-10-03"}],"displaytype":"detail","filename":"ME-PR-TAKAMATSU-H-541.pdf","filesize":[{"value":"391.3 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ME-PR-TAKAMATSU-H-541.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/14495/files/ME-PR-TAKAMATSU-H-541.pdf"},"version_id":"3fc46946-b7b5-47e4-9742-3310d57d89a1"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Aplastic anemia successfully treated with rituximab: The possible role of aplastic anemia-associated autoantibodies as a marker for response","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Aplastic anemia successfully treated with rituximab: The possible role of aplastic anemia-associated autoantibodies as a marker for response"}]},"item_type_id":"4","owner":"3","path":["1134"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-10-03"},"publish_date":"2017-10-03","publish_status":"0","recid":"14495","relation_version_is_last":true,"title":["Aplastic anemia successfully treated with rituximab: The possible role of aplastic anemia-associated autoantibodies as a marker for response"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-07-28T00:46:43.608331+00:00"}